Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

Bristol-Myers Squibb Company

Overview
Date Founded

1933

Headquarters

345 Park Avenue,New York, NY 10154

Type of Company

Public

Employees (Worldwide)

23.3K

Industries

Pharmaceuticals
Medical Support Services
Hospitals & Patient Services
Biotechnology

Company Description

Bristol-Myers Squibb Company Our company has a strong legacy of innovation that began in New York in 1858 when Edward R. Squibb, M.D., founded a pharmaceutical company in Brooklyn, and in 1887 when two friends, William McLaren Bristol and John Ripley Myers purchased a struggling drug manufacturing firm in Clinton. Together, they laid the foundation for our company today — a global BioPharma leader that continues this legacy of innovation.

Contact Data
Trying to get in touch with decision makers at Bristol-Myers Squibb Company? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

Head-Corporate & Employee Communications

Executive Vice President, General Counsel

Executive Vice President, Chief Commercialization Officer

Senior Vice President & Chief Information Officer

Chief Scientific Officer & Executive Vice President

Senior Vice President & Chief Human Resources Officer

Senior Vice President & Head of Business Development

President, Global Product Development & Supply

Senior Vice President & Controller

Board of Directors

Chief Executive Officer at Bristol-Myers Squibb Company

Former Partner at Ernst & Young LLP

Director at Western Union Financial Services, Inc.

Former President & Chief Financial Officer at Bausch + Lomb, Inc.

Former Chief Executive Officer at OraPharma, Inc.

Chairman & Co-Founder at Vir Biotechnology, Inc.

Former President & Chief Executive Officer at Vertex Pharmaceuticals, Inc.

Chief Executive Officer at Integra Lifesciences Holdings Corp.

Former Director & President at Capital Guardian Trust Co.

Former Partner at McKinsey & Co., Inc.

Paths to Bristol-Myers Squibb Company
Potential Connections via
Relationship Science
You
Bristol-Myers Squibb Company
Owners & Shareholders
Details Hidden

Wellington Management's investment services rely on their extensive independent research and include portfolio management styles and approaches in equities, fixed income securities, currencies and commodities, as well as asset allocation across these categories. The firm has a number of different disciplines when approaching research and these include asset allocation analysts, currency analysts, data scientists, factor analysts, fixed income credit analysts, fixed income market analysts, global industry analysts and research associates, macroanalysts, quantitative analysts and technical analysts. Wellington Management's portfolio management teams often include dedicated analysts who evaluate securities and other instruments for suitability based on the team's investment approach. The firm supplements their internal research with external research from sources such as broker/dealers and third-party research firms. These sources typically provide data, research and analysis and may serve as a gauge of market consensus.

Details Hidden

Dodge & Cox's investment decisions are made by a team of seasoned investment professionals based on key fundamental factors that they believe determine investment value over the long term. The firm's investment analysts operate from a single location to foster communication and collaboration and each investment idea is subject to committee review for both its merits as a specific investment and its role in the overall portfolio. Their approach stresses an evaluation of risk relative to opportunity and we seek investments that we believe are undervalued by the market. Fundamental bottom-up research, a rigorous valuation discipline and a long-term investment horizon are central to Dodge & Cox's investment philosophy.

Details Hidden

PRIMECAP invests primarily common stocks or securities with common stock characteristics, bonds and cash/cash equivalents. The firm utilizes fundamental research and bottom-up stock picking to construct portfolios. The main sources of information for research purposes include financial publications, inspections of corporate activities, research materials by others such as sell-side analysts, companies' annual reports and any related filings and press releases, meetings with executives of companies and their suppliers, competitors, customers, etc. All portfolios are built with the best ideas of each of the managers within the multi-manager investment process. PRIMECAP's investment strategy does not employ short sales or margin transactions, nor does it permit investments in derivatives or currency hedging. The firm follows an investment approach based on four key principles including commitment to fundamental research, long-term investment horizon, emphasis on individual decision-making and focus on value.

Recent Transactions
Details Hidden

Catalent, Inc. purchases Bristol-Myers Squibb Co. /Anagni Manufacturing Facility from Bristol-Myers Squibb Company

Details Hidden

Bristol-Myers Squibb Company purchases Celgene Corp.

Details Hidden

SK Holdings Co., Ltd., SK Biotek, Inc. purchase Bristol Myers Squibb Co /Pharmaceutical Facility from Bristol-Myers Squibb Company

Insider Transactions
Details Hidden
Transaction Advisors
Legal Advisor

Advised onBristol-Myers Squibb Company purchases DuPont Pharmaceuticals Co. from DuPont

Legal Advisor

Advised onBristol-Myers Squibb Company purchases Celgene Corp.

Accountant

Advised onBristol-Myers Squibb Company purchases DuPont Pharmaceuticals Co. from DuPont

Legal Advisor

Advised onBristol-Myers Squibb Company purchases Celgene Corp.

Legal Advisor

Advised onBristol-Myers Squibb Company purchases Amylin Pharmaceuticals, Inc.

Legal Advisor

Advised onBristol-Myers Squibb Company purchases Celgene Corp.

Advisors & Consultants
Legal Advisor

Partner at Sidley Austin LLP

Legal Advisor

Shareholder at Greenberg Traurig LLP

Legal Advisor

Partner at Wilmer Cutler Pickering Hale and Dorr LLP

Clients

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. It product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988 and is headquartered in Tarrytown, NY.

Acorda Therapeutics, Inc. engages in the development of therapies that restore function and improve the lives of people with neurological disorders. Its two main products are Ampyra and Zanaflex Capsules. The Ampyra is an oral drug, which treats to improve walking in patients with multiple sclerosis and Zanaflex Capsules, which is a short acting drug for the management of spasticity, a symptom of many central nervous system disorders, including multiple sclerosis and spinal cord injury. The company was founded by Ronald Cohen in 1995 and is headquartered in Ardsley, NY.

Key Stats and Financials As of 2018
Market Capitalization
$83.1B
Total Enterprise Value
$83.7B
Earnings Per Share
$3.01
Revenue
$22.6B
Net Profit
$4.92B
EBITDA
$7.1B
EBITDAMargin
31.46%
Total Debt
$7.35B
Total Equity
$14.1B
Enterprise Value Sales
3.71x
TEVNet Income
17x
Debt TEV
0.09x
Enterprise Value EBITDAOperating
11.79x
Three Year Compounded Annual Growth Rate Of Revenue
10.86%
Five Year Compounded Annual Growth Rate Of Revenue
6.61%
Non-Profit Donations & Grants
Non-Profit Donations & Grants Received
Political Donations
$500
2012
$250
2012
$500
2011
Investments
Details Hidden

Allied-Bristol Life Sciences LLC engages in the development of biopharmaceutical innovations. It creates a paradigm of drug discovery and incubation that benefits individuals and treatment options for health conditions. Its therapeutic area of interest are cardiovascular and genetically defined diseases, immunology, oncology, and virology. The company was founded in 2014 and is headquartered in Boston, MA.

Details Hidden

Enterome SA develops personalized medical-tests and diagnostics. The firm profiles human gut microbiome to improve management of microbiome-related disease. It primarily specializes in research adn development focusing on disease management. The company was founded by Stanislav Dusko Ehrlich in 2012 and is headquartered in Paris, France.

Details Hidden

Vedanta Biosciences, Inc. develops microbial therapies that address the human immune system. The firm engages in the development of a new class of drugs that work by modulating the human microbiome, with an initial emphasis in autoimmune and inflammatory diseases. The company was founded by Ruslan Medzhitov, Alexander Rudensky, Brett Finlay, Kenya Honda, Dan Littman, Bernat Olle and David Steinberg in 2010 and is headquartered in Boston, MA.

Investors
Details Hidden

Co-Founder at Starboard Value LP

Details Hidden

Founder at Foresite Capital Management LLC

Details Hidden

Co-Founder at Washington Research Foundation

Suppliers
Alexandria Real Estate Equities, Inc. Trusts & Funds | Pasadena, CA

Alexandria Real Estate Equities, Inc. is an urban office real estate investment trust, which engages in the ownership, operation, development, and redevelopment of life science and technology properties. It also provides a space for lease to the life science and technology industries which are primarily located in AAA urban innovation cluster locations. The company was founded by Alan D. Gold, Gary A. Kreitzer, Joel S. Marcus, and Jerry M. Sudarsky in October 1994 and is headquartered in Pasadena, CA.

TSR, Inc. Auto Parts & Tires | Hauppauge, NY

TSR, Inc. engages in the provision of contract computer programming and staffing services. It supports its clients with technical computer personnel to supplement their in-house information technology capabilities. The company was founded in 1969 and is headquartered in Hauppauge, NY.

Portola Pharmaceuticals, Inc. Pension Funds & Sovereign Wealth | SOUTH SAN FRANCISCO, CA

Portola Pharmaceuticals, Inc. engages in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. It offers Andexxa, and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA.

Competitors
Merck & Co., Inc. Pharmaceuticals - Kenilworth, NJ

Merck & Co., Inc. , d.b.a. Merck Sharp & Dohme, MSD outside the United States and Canada, is an American pharmaceutical company and is one of the largest pharmaceutical companies in the world.

Johnson & Johnson Pharmaceuticals - New Brunswick, New Jersey

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women's health, and wound care markets. The Pharmaceutical segment focuses on therapeutic areas such as immunology, infectious diseases ad vaccines, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The Medical Devices segment offers products used in the orthopedic, surgery, cardiovascular, diabetes care, and eye health fields. The company was founded by Robert Wood Johnson I, James Wood Johnson and Edward Mead Johnson Sr. in 1886 and is headquartered in New Brunswick, NJ.

Amgen, Inc. Biotechnology - Thousand Oaks, CA

Amgen, Inc. is a biotechnology medicines company, which discovers, develops, manufactures and markets medicines for grievous illnesses. The company focuses on human therapeutics and concentrates on innovating novel medicines based on advances in cellular and molecular biology. It markets recombinant protein therapeutics in supportive cancer care, nephrology and inflammation. The company's products include Neulasta, a pegylated protein, based on the Filgrastim molecule and NEUPOGEN, a recombinant-methionyl human granulocyte colony stimulating factor both of which selectively stimulate the production of neutrophils; Enbrel, an inhibitor of tumor necrosis factor, a substance that plays a role in the body's response to inflammatory diseases; Sensipar/Mimpara, a small molecule calcimimetic that lowers serum calcium levels; Vectibix, a monoclonal antibody that binds specifically to the epidermal growth factor receptor; and Nplate, a thrombopoietin receptor agonist that mimics endogenous TPO, the primary driver of platelet production. Amgen was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Awards & Honors
Rank #168
2016
Fortune Magazine - Fortune 1000 Companies
Sponsored by Fortune Magazine
Rank #168
2016
Fortune Magazine - Fortune 500 Companies
Sponsored by Fortune Magazine
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Bristol-Myers Squibb Company. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Bristol-Myers Squibb Company's profile does not indicate a business or promotional relationship of any kind between RelSci and Bristol-Myers Squibb Company.